Abstract | BACKGROUND: METHODS: We performed targeted deep sequencing of plasma cell-free DNA ( cfDNA) by massively parallel sequencing in patients with tumours harbouring TP53 mutations. The quantitative values of TP53-ctDNA during the clinical course were compared with the tumour status. RESULTS: Three out of ten patients with TP53 mutations in primary tumours showed detectable TP53 mutation levels in preoperative cfDNA. Although the cfDNA concentrations were not always reflective of the disease course, the ctDNA fraction correlated with the disease status. CONCLUSIONS:
|
Authors | T Hamakawa, Y Kukita, Y Kurokawa, Y Miyazaki, T Takahashi, M Yamasaki, H Miyata, K Nakajima, K Taniguchi, S Takiguchi, M Mori, Y Doki, K Kato |
Journal | British journal of cancer
(Br J Cancer)
Vol. 112
Issue 2
Pg. 352-6
(Jan 20 2015)
ISSN: 1532-1827 [Electronic] England |
PMID | 25490524
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers, Tumor
- DNA, Neoplasm
- TP53 protein, human
- Tumor Suppressor Protein p53
|
Topics |
- Aged
- Aged, 80 and over
- Biomarkers, Tumor
(blood)
- DNA Mutational Analysis
- DNA, Neoplasm
(blood)
- Disease Progression
- High-Throughput Nucleotide Sequencing
- Humans
- Lymphatic Metastasis
- Male
- Neoplasm, Residual
- Prospective Studies
- Stomach Neoplasms
(blood, pathology, surgery)
- Tumor Suppressor Protein p53
(genetics)
|